Aldeyra Therapeutics, Inc.
47.1M
$78.84M
-9.19
$-0.56
No price alerts set. Add an alert to get notified!
-9.19
0.00
$-0.56
0.00%
0.00%
0.00%
Compare TSM with similar companies in the sector
| Company | Price | Change % | P/E | Market Cap | D/E |
|---|---|---|---|---|---|
|
ACIU
AC Immune S.A.
|
$3.25 | 3.83% | -3.67 | $326.95M | 0.10 |
|
AMRN
Amarin Corporation plc
|
$15.44 | 0.10% | -165.50 | $319.24M | 0.03 |
|
ANRO
Alto Neuroscience, Inc.
|
$23.86 | -1.77% | -10.39 | $737.20M | 0.25 |
|
CADL
Candel Therapeutics, Inc.
|
$5.14 | 2.98% | -7.39 | $281.64M | 0.04 |
|
CLLS
Cellectis S.A.
|
$3.46 | -1.14% | -10.22 | $347.06M | 0.92 |
|
CTNM
Contineum Therapeutics, Inc. Class A Common Stock
|
$13.39 | 0.15% | -6.89 | $489.31M | 0.03 |
|
GNLX
Genelux Corporation
|
$2.59 | -1.52% | -3.08 | $97.43M | 0.09 |
|
KYTX
Kyverna Therapeutics, Inc.
|
$8.83 | -2.84% | -2.38 | $387.12M | 0.03 |
|
MREO
Mereo BioPharma Group plc
|
$0.38 | -5.41% | -1.45 | $60.24M | 0.01 |
|
SLN
Silence Therapeutics plc
|
$6.93 | -5.71% | -3.69 | $327.33M | 0.00 |
* Peer stocks are selected based on market capitalization and sector
$6.87
$1.07
$0.00
0.00%
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It also develops ADX-629, a first-in-class orally administered RASP modulator that is Phase II clinical trial for psoriasis, asthma, and COVID-19; and ADX-2191, a dihydrofolate reductase inhibitor which is in phase 3 for the prevention of proliferative vitreoretinopathy, and phase II clinical trial for the treatment of retinitis pigmentosa, as well as for treating primary vitreoretinal lymphoma. The company has a license agreement with Madrigal Pharmaceuticals, Inc. for developing ADX-1612, which inhibits the protein chaperome for the treatment of inflammatory diseases. The company was formerly known as Aldexa Therapeutics, Inc. and changed its name to Aldeyra Therapeutics, Inc. in March 2014. Aldeyra Therapeutics, Inc. was incorporated in 2004 and is based in Lexington, Massachusetts.
